Gå frakoblet med Player FM -appen!
Mitigating Muscle Loss from GLP-1 Agonists, with Dr. Anurag Singh
Manage episode 414607535 series 1149419
Even as we prioritize natural interventions in functional medicine, GLP-1 agonist drugs such as Wegovy and Ozempic offer sometimes life-changing support for those who have long struggled with resistant overweight/obesity and high blood sugar. However, there are side effects, including the risk of substantial muscle loss and sagging, aged skin ("Ozempic face" as it's indelicately known). It's a concern that hits home for me, considering the pivotal role we know that muscle plays in overall health and longevity.
In this New Frontiers podcast episode I welcome back Dr. Anurag Singh to unravel the complexities of these issues. We explore the interplay between metabolic health and muscle preservation, touching on everything from the mechanisms of GLP-1 agonists and their long-term effects on aging and sarcopenia, to the promising potential of dietary and lifestyle interventions to counteract negative effects. We consider the potential for one of my all-time fave postbiotic epinutrients - Urolithin A - to assist by supporting mitochondrial health and preserving/enhancing muscle quality. This timely conversation is one you won't want to miss. Tune in and please leave us a review wherever you listen to New Frontiers. – DrKF
Check out our show notes https://www.drkarafitzgerald.com/fxmed-podcast/
Guest information
Anurag Singh, MD, PhD
Chief Medical Officer at Timeline
Thank you to our sponsor
- Timeline
- Mitopure
- Research from Timeline
- care@timeline.com
Timeline Discount for New Frontiers Listeners
Timeline is offering DrKFs readers a 10% discount on Timeline products. Head over to Timeline and use the code KARA10 at checkout.
Show Notes
- Study: Once-Weekly Semaglutide in Adults with Overweight or Obesity https://tinyurl.com/y3c2ypkw
184 episoder
Mitigating Muscle Loss from GLP-1 Agonists, with Dr. Anurag Singh
Dr. Kara Fitzgerald | New Frontiers in Functional Medicine, Longevity, Epigenetics
Manage episode 414607535 series 1149419
Even as we prioritize natural interventions in functional medicine, GLP-1 agonist drugs such as Wegovy and Ozempic offer sometimes life-changing support for those who have long struggled with resistant overweight/obesity and high blood sugar. However, there are side effects, including the risk of substantial muscle loss and sagging, aged skin ("Ozempic face" as it's indelicately known). It's a concern that hits home for me, considering the pivotal role we know that muscle plays in overall health and longevity.
In this New Frontiers podcast episode I welcome back Dr. Anurag Singh to unravel the complexities of these issues. We explore the interplay between metabolic health and muscle preservation, touching on everything from the mechanisms of GLP-1 agonists and their long-term effects on aging and sarcopenia, to the promising potential of dietary and lifestyle interventions to counteract negative effects. We consider the potential for one of my all-time fave postbiotic epinutrients - Urolithin A - to assist by supporting mitochondrial health and preserving/enhancing muscle quality. This timely conversation is one you won't want to miss. Tune in and please leave us a review wherever you listen to New Frontiers. – DrKF
Check out our show notes https://www.drkarafitzgerald.com/fxmed-podcast/
Guest information
Anurag Singh, MD, PhD
Chief Medical Officer at Timeline
Thank you to our sponsor
- Timeline
- Mitopure
- Research from Timeline
- care@timeline.com
Timeline Discount for New Frontiers Listeners
Timeline is offering DrKFs readers a 10% discount on Timeline products. Head over to Timeline and use the code KARA10 at checkout.
Show Notes
- Study: Once-Weekly Semaglutide in Adults with Overweight or Obesity https://tinyurl.com/y3c2ypkw
184 episoder
Alle episoder
×Velkommen til Player FM!
Player FM scanner netter for høykvalitets podcaster som du kan nyte nå. Det er den beste podcastappen og fungerer på Android, iPhone og internett. Registrer deg for å synkronisere abonnement på flere enheter.